Episode Player
262: How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alternative expression platforms and offers a clear, practical framework for scientists navigating host cell decisions today. David Brühlmann moves past simplistic "replacement" narratives to instead examine where each technology, from plant farming to cell-free systems, fits in today’s market and production realities.
Key topics discussed
- Why asking if a novel host will "replace CHO" is the wrong question for scientists and manufacturers (00:11)
- Critical dimensions to evaluate: cost structure, speed, and intrinsic product quality (01:20)
- Review of five alternative platforms with current clinical and regulatory status:
- Plant farming for speed and decentralization (03:42)
- Insect cells for VLPs and complex proteins (05:00)
- Cell-free protein synthesis for ADCs and unique conjugation requirements (06:23)
- Moss for monoclonal antibodies with distinct glycosylation patterns (07:50)
- Filamentous fungi for high secretion and thermotolerance (08:47)
- A practical host selection framework by molecule type and manufacturing context (09:59)
- Detailed constraints and advantages of each platform, including cost, infrastructure, timeline, and product attributes (10:09)
- Analysis of silkworm production as a disruptive possibility for future biologics manufacturing (13:09)
- The evolving toolkit available to bioprocess scientists—and why "CHO replacement" is a distraction from more relevant questions (12:06)
Smart insight:
The real development over the past decade is that bioprocess scientists now have a credible, validated toolkit of alternatives for specific molecules in specific contexts. The practical implication: know this landscape well enough to ask the right host selection question at program initiation, before you've built months of process development around a platform you chose by default.
Here are the episodes referenced:
- Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
- Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
- Episodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen
- Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
- Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran
Next:
If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.
